During the past decade, Oklahoma Center for Bleeding and Clotting Disorders conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oklahoma Center for Bleeding and Clotting Disorders" #1 collaborator was "CSL Behring" with 1 trials as a collaborator, "LFB USA, Inc." with 1 trials as a collaborator, "Octapharma" with 1 trials as a collaborator and "Takeda" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Oklahoma Center for Bleeding and Clotting Disorders" are "Hemophilia A With Inhibitor" (2 trials), "Hemophilia B With Inhibitor" (2 trials), "Haemophilia" (1 trials), "Haemophilia A Without Inhibitor" (1 trials) and "Haemophilia B Without Inhibitor" (1 trials). Many other conditions were trialed in "Oklahoma Center for Bleeding and Clotting Disorders" in a lesser frequency.

Most popular intervention types in "Oklahoma Center for Bleeding and Clotting Disorders" are "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "coagulation factor VIIa [recombinant]-jncw" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oklahoma Center for Bleeding and Clotting Disorders" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Oklahoma Center for Bleeding and Clotting Disorders". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Oklahoma Center for Bleeding and Clotting Disorders, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Oklahoma Center for Bleeding and Clotting Disorders, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".